Pirfenidone bulk supplier for pharma manufacturers

Pirfenidone Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 267 mg , 801 mg

Reference Brands: Esbriet®(US & EU)

Category: Respiratory Disorder

Pirfenidone is available in Tablet and strengths such as 267 mg , 801 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Pirfenidone is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Pirfenidone can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description: Pirfenidone is an FDA- and EMA-approved oral antifibrotic drug used to treat idiopathic pulmonary fibrosis (IPF)—a chronic lung disease marked by progressive scarring of lung tissue. Marketed under the brand name Esbriet, pirfenidone helps slow lung function decline, reduce inflammation, and limit fibrosis by inhibiting pro-fibrotic cytokines like TGF-β. Available in 267 mg and 801 mg tablet strengths, it is usually taken three times daily with food. Pirfenidone improves quality of life and delays disease progression in IPF patients. Common side effects include nausea, rash, and photosensitivity. Regular liver monitoring is advised during treatment.

Frequently Asked Questions

Yes, Pirfenidone is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Pirfenidone is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Fluticasone Furoate + Vilanterol

Strength:
92 mcg Fluticasone furoate / 22 mcg Vilanterol; 184 mcg Fluticasone furoate / 22 mcg Vilanterol

Form: Powder For Inhalation(DPI/MDI)

Reference Brands: Breo Ellipta®(US), Relvar Ellipta® (EU)

View Details
Mometasone + Formoterol

Strength:
100 mcg/5 mcg , 200 mcg/5 mcg

Form: Inhaler(MDI)

Reference Brands: Dulera®(US)

View Details
Ambroxol Hydrochloride

Strength:
Tab: 30 mg, 60 mg; Syrup: 15 mg/5 mL, 30 mg/5 mL; Drops: 7.5 mg/mL, 15 mg/mL

Form: Tablets, Syrup & Oral drops

Reference Brands: Mucosolvan®, Flavamed®, Ambrobeta®, Ambroxol-ratiopharm®(EU)

View Details
Carbocisteine

Strength:
Cap: 375 mg and 750 mg; Oral Solution: 50 mg/5 mL and 750 mg/5 mL

Form: Capsules, Oral Solutions/Syrups

Reference Brands: Mucodyne, Lisomucil®, Rhinathiol®, Muciclar®, Actithiol®, Mucolex®(US)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.